AstraZeneca stock gets EU backing for Baxfendy
Published on 11/16/2026 at 10:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEuropean recommendation adds a pipeline milestone
- A European medicines committee recommended Baxdrostat for marketing authorisation in the European Union.
- Baxfendy could become the first drug of its class to reach patients in the EU.
A European medicines committee recommended AstraZeneca's hypertension drug baxdrostat, branded as Baxfendy, for marketing authorisation on Friday, November 13, Reuters reported. The recommendation covers adults whose hypertension remains insufficiently controlled despite treatment with at least two medicines.
The Committee for Medicinal Products for Human Use, or CHMP, backed the medicine after reviewing results from two late-stage clinical trials. AstraZeneca said Baxfendy could become the first drug in its class to reach patients in the European Union, giving the company another regulatory milestone in its cardiovascular portfolio.
What the recommendation means
Baxdrostat uses a different approach from older blood-pressure treatments by blocking the hormone aldosterone. The medicine is already approved in the United States and other countries, while regulatory reviews are under way in Japan and China, according to Reuters.
AstraZeneca acquired baxdrostat through its 2023 purchase of CinCor Pharma for 1.8 billion US dollars. The European recommendation therefore advances an asset that has been part of AstraZeneca's pipeline since that transaction. A marketing authorisation would create another geographic route for the drug, although commercial performance will depend on the final regulatory process, launch timing and uptake among eligible patients.
Reuters reported that final access to the European market remains tied to the recommendation's regulatory status. Investors will therefore focus on the next European decision and on evidence of demand after any launch.
AstraZeneca stock traded at 168.40 euros on Lang & Schwarz at 10:15 CET on Monday, November 16.
AstraZeneca at a glance
- Company: AstraZeneca PLC
- ISIN: GB0009895292
- Lang & Schwarz quote: 168.40 euros, Monday, November 16, 2026, 10:15 CET
Broader market coverage is available in Current market reports.
